| scholarly article | Q13442814 |
| P356 | DOI | 10.1023/A:1007552927404 |
| P698 | PubMed publication ID | 10751026 |
| P2093 | author name string | T C Wu | |
| S M Chung | |||
| H Y Jeong | |||
| W L Chiou | |||
| P2860 | cites work | Comparison between permeability coefficients in rat and human jejunum | Q34063545 |
| Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats | Q34067981 | ||
| The phenomenon and cause of the dose-dependent oral absorption of chlorothiazide in rats: extrapolation to human data based on the body surface area concept | Q36473637 | ||
| Comparison of canine and human gastrointestinal physiology | Q38165787 | ||
| Absorption of the β-Adrenergic-Blocking Agent, Nadolol, by Mice, Rats, Hamsters, Rabbits, Dogs, Monkeys, and Man: An Unusual Species Difference | Q39210510 | ||
| Apparent dose-dependent absorption of chlorothiazide in dogs | Q39297597 | ||
| Pharmacokinetics/pharmacodynamics of furosemide in man: A review | Q39933352 | ||
| Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals | Q40926487 | ||
| Species similarities and differences in pharmacokinetics. | Q41001138 | ||
| Pharmacokinetics and bioavailability of acyclovir in the dog. | Q42671894 | ||
| Studies on the pharmacokinetics and pharmacodynamics of atenolol in man | Q44266262 | ||
| Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides | Q47289212 | ||
| Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. | Q48687795 | ||
| New perspectives on the theory of permeability and resistance in the study of drug transport and absorption. | Q52299578 | ||
| Ranitidine bioavailability and kinetics in normal male subjects | Q52707225 | ||
| Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man | Q67284916 | ||
| Metabolic disposition and pharmacokinetics of pelrinone, a new cardiotonic drug, in laboratory animals and man | Q68883143 | ||
| Absorption of iothalamate after oral administration: a preliminary study in humans and interspecies differences | Q69015996 | ||
| Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril | Q69364366 | ||
| Pharmacokinetic studies with atenolol in the dog | Q71061977 | ||
| Absorption and disposition of ranitidine hydrochloride in rat and dog | Q71728610 | ||
| Single dose pharmacokinetics of sumatriptan in healthy volunteers | Q72281602 | ||
| The metabolism of ICI 118,587, a partial agonist of beta 1-adrenoceptors, in mice, rats, rabbits, dogs, and humans | Q72592492 | ||
| Disposition of sumatriptan in laboratory animals and humans | Q72658483 | ||
| Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption | Q77974422 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 135-140 | |
| P577 | publication date | 2000-02-01 | |
| P1433 | published in | Pharmaceutical Research | Q7180737 |
| P1476 | title | Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. | |
| P478 | volume | 17 |
| Q89575961 | A Novel Systematic Approach for Selection of Prodrugs Designed to Improve Oral Absorption |
| Q78578799 | ADME evaluation. 2. A computer model for the prediction of intestinal absorption in humans |
| Q30940461 | Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data? |
| Q91895343 | Animal to human translation: a systematic scoping review of reported concordance rates |
| Q42744069 | Animal versus human oral drug bioavailability: do they correlate? |
| Q73633682 | Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice |
| Q41986693 | Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls. |
| Q36065586 | Challenges and opportunities in achieving bioequivalence for fixed-dose combination products |
| Q38151571 | Chimeric mice transplanted with human hepatocytes as a model for prediction of human drug metabolism and pharmacokinetics |
| Q35553211 | Clinical Pharmacokinetics of Atorvastatin |
| Q39739399 | Clinical pharmacokinetics of the cyclooxygenase inhibiting nitric oxide donator (CINOD) AZD3582. |
| Q33749474 | Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers |
| Q74604259 | Comparison of gastrointestinal absorption between human and rat: the role of intestinal absorptive surface area and unstirred aqueous layer |
| Q78483345 | Comparison of gastrointestinal absorption between human and rat: the role of intestinal absorptive surface area and unstirred aqueous layer(1) |
| Q44074776 | Comparison of oral absorption and bioavailablity of drugs between monkey and human |
| Q79750339 | Dog colonoscopy model for predicting human colon absorption |
| Q36341582 | Drug compounding for veterinary patients |
| Q44003564 | Effect of physicochemical and formulation variables on the in vivo absorption of ABT-761. |
| Q52783790 | Establishment of a mouse model of enalapril-induced liver injury and investigation of the pathogenesis. |
| Q88959617 | Evaluation of Using Dogs to Predict Fraction of Oral Dose Absorbed in Humans for Poorly Water-Soluble Drugs |
| Q30782163 | Evaluation of rat intestinal absorption data and correlation with human intestinal absorption |
| Q35156106 | Expandable gastroretentive dosage forms |
| Q33488925 | Exploratory population pharmacokinetics (e-PPK) analysis for predicting human PK using exploratory ADME data during early drug discovery research |
| Q49065618 | Feasibility of the Ussing chamber technique for the determination of in vitro jejunal permeability of passively absorbed compounds in different animal species |
| Q33596496 | Functionalized carbon nanotubes as suitable scaffold materials for proliferation and differentiation of canine mesenchymal stem cells |
| Q37600381 | Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination |
| Q46965287 | In vivo performance of an oral MR matrix tablet formulation in the beagle dog in the fed and fasted state: assessment of mechanical weakness |
| Q35070464 | Issues related to the use of canines in toxicologic pathology--issues with pharmacokinetics and metabolism |
| Q38801524 | Key Considerations in Designing Oral Drug Delivery Systems for Dogs |
| Q39038877 | Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions |
| Q46868096 | Pharmacokinetic profiles of the analgesic drug flupirtine in cats. |
| Q37148216 | Pharmacokinetics and Metabolism of Cyadox and Its Main Metabolites in Beagle Dogs Following Oral, Intramuscular, and Intravenous Administration |
| Q47823002 | Pharmacokinetics and disposition of flupirtine in the horse. |
| Q34581581 | Physiologically-based pharmacokinetic simulation modelling. |
| Q39717253 | Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. |
| Q36609758 | Preclinical formulations for discovery and toxicology: physicochemical challenges |
| Q44738634 | Preclinical pharmacokinetics and metabolism of a potent non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase |
| Q26764739 | Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models |
| Q92580245 | Prediction Accuracy of Mechanism-Based Oral Absorption Model for Dogs |
| Q33437736 | Prediction of hepatic clearance in human from in vitro data for successful drug development |
| Q39805145 | Prediction of human pharmacokinetics--evaluation of methods for prediction of hepatic metabolic clearance |
| Q36885247 | Prediction of human pharmacokinetics--gastrointestinal absorption |
| Q38177366 | Pros and cons of methods used for the prediction of oral drug absorption. |
| Q40606599 | Quantifying and Communicating Uncertainty in Preclinical Human Dose-Prediction |
| Q46534443 | Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation. |
| Q31049599 | Recent advances in pharmacokinetic extrapolation from preclinical data to humans |
| Q46556849 | Species differences in intestinal glucuronidation activities between humans, rats, dogs and monkeys |
| Q37065418 | The conduct of drug metabolism studies considered good practice (I): analytical systems and in vivo studies |
| Q97093738 | The past, present and future of intestinal in vitro cell systems for drug absorption studies |
| Q30670381 | The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data. |
| Q96603948 | Understanding Pharmacokinetic Disconnect in Preclinical Species for 4-Aminoquinolines: Consequences of Low Permeability and High P-glycoprotein Efflux Ratio on Rat and Dog Oral Pharmacokinetics |
Search more.